# Kangwei (Guangzhou) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangwei-guangzhou-biotechnology-co

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Total disclosed funding: $46M
- Latest round: Series A (Aug 10, 2022)
- Investors on record: 6

## About

Based in Guangzhou, China, and founded in 2018, Kangwei (Guangzhou) Biotechnology Co., Ltd operates as a manufacturer of anti-tumor drugs, focusing on providing cancer treatment drugs for patients. Its founding team has completed the research and development and FDA application of more than 50 new drugs, and clinical development of 40 new drugs. 

The company has established three technology platforms and a pipeline of new anti-tumor drugs, including immunotherapy platform, small molecule and coupling platform, and antibody drug coupling (ADC) platform. Its immunotherapy platform includes 2 clinical trial stage drugs, CAN1012 and DPV-001, which are therapeutic oncology vaccines.

## Funding rounds

- Series A, Aug 10, 2022, $15M — SDIC Venture Capital
- Series A, Mar 18, 2022, $31M — CAS Investment Management, China Capital Management, Lapam Capital, Jiuyo Capital, Milestep capital management(Hengqin)

## Investors

- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series A
- Milestep capital management(Hengqin) — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A